טוען...
Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma
Atrasentan is an oral selective endothelin-A receptor antagonist that may inhibit cell proliferation and interfere with angiogenesis during glioma growth. We conducted a dose-finding study to assess atrasentan’s safety and toxicity and to gather preliminary evidence of efficacy. Patients with recurr...
שמור ב:
| Main Authors: | , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Duke University Press
2008
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2666236/ https://ncbi.nlm.nih.gov/pubmed/18477765 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1215/15228517-2008-013 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|